If there is a generalisation outside of person centred care, and patients remain stable on the drug, then in the first year patient's tend to be scanned 3 monthly, with medical or ANP follow up depending on model of care for results
In our local practice of West Kent, management of patients' on this treatment in the first few months are non medical review only, and follow up, either face to face or telephone consultation. I believe a non medical model is adapted commonly throughout the country as well to manage the additional demand of resource required for patient review
We are more frequently extending time points between scans unless clinically indicated, which again makes it difficult to be prescriptive in response. Again not all reviews remain within a medical model, ie seen only by Consultant Oncologist as boundaries of non medical roles are developing
Not sure if that helps?
This is difficult to answer as this population require an individualized approach to their care.
Provided patients are stable and coping well we tend to follow up with medical review then nurse led telephone follow 8 weeks post medical review and CT every 16 weeks. We always see them for face to face consultation to give scan results. This is with the patients knowing we have an open door policy and we will call them or see them in between if they have unmet needs.
The policy team is currently responding to a NICE consultation for secondary breast cancer and would like your input on a particular question.
From your experience, broadly speaking, how frequently do people on a CDK 4/6 inhibitor have appointments with a consultant oncologist on the NHS in England? There is clearly a protocol for monitoring/review in the initial period, but how about once the patient is established on the drug?
Senior Policy Lead